Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The therapeutic effect of targeted kinase inhibitors can be significantly reduced by intrinsic or acquired resistance mutations that modulate the affinity of the drug for the kinase. In cancer, the majority of missense mutations are rare, making it difficult to predict their impact on inhibitor affinity. We examine the potential for alchemical free-energy calculations to predict how kinase mutations modulate inhibitor affinities to Abl, a major target in chronic myelogenous leukemia (CML). These calculations have useful accuracy in predicting resistance for eight FDA-approved kinase inhibitors across 144 clinically identified point mutations, with a root mean square error in binding free-energy changes of $$1.1_{0.9}^{1.3}$$ 1 . 1 0.9 1.3 kcal mol −1 (95% confidence interval) and correctly classifying mutations as resistant or susceptible with $$88_{82}^{93}$$ 8 8 82 93 % accuracy. This benchmark establishes the potential for physical modeling to collaboratively support the assessment and anticipation of patient mutations to affect drug potency in clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 5×
“To generate models of these complexes, Glide-SP [66] was utilized to dock these two compounds into an Abl receptor structure.”
MethodInfluentialCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“, induction of splice 32 variants [16], or alleviation of feedback [17]), inherent or acquired missense mutations in the kinase domain 33 of the target of therapy are a major form of resistance to tyrosine kinase inhibitors (TKI) [10, 18, 19].”
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“(a) Missense mutation statistics derived from 10,336 patient samples subjected to MSK-IMPACT deep sequencing panel [20] show that 68.”
BackgroundA comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Wang, L., Wu, Y., Deng, Y., Kim, B., Pierce, L., Krilov, G., Lupyan, D., Robinson, S., Dahlgren, M. K., Greenwood, J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512751q · Cited by 1,313 · cited 4×
“0 kcal/mol for CDK2, JNK1, p38, and Tyk2 [29, 30].”
BackgroundMethodInfluentialSelf-citationAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967 · cited 1×
“, induction of splice 32 variants [16], or alleviation of feedback [17]), inherent or acquired missense mutations in the kinase domain 33 of the target of therapy are a major form of resistance to tyrosine kinase inhibitors (TKI) [10, 18, 19].”
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674 · cited 1×
“, induction of splice 32 variants [16], or alleviation of feedback [17]), inherent or acquired missense mutations in the kinase domain 33 of the target of therapy are a major form of resistance to tyrosine kinase inhibitors (TKI) [10, 18, 19].”
Accurate calculation of the absolute free energy of binding for drug molecules
Aldeghi, M., Heifetz, A., Bodkin, M. J., Knapp, S., & Biggin, P. C. (2016) · Chemical Science · doi:10.1039/c5sc02678d · Cited by 347
Cited by
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
The maximal and current accuracy of rigorous protein-ligand binding free energy calculations
Ross, G. A., Lu, C., Scarabelli, G., Albanese, S. K., Houang, E., Abel, R., Harder, E. D., & Wang, L. (2023) · Communications Chemistry · doi:10.1038/s42004-023-01019-9 · Cited by 178
Self-citationFGFR-TKI resistance in cancer: current status and perspectives
Yue, S., Li, Y., Chen, X., Wang, J., Li, M., Chen, Y., & Wu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01040-2 · Cited by 145
Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0968 · Cited by 52
A mutation-induced drug resistance database (MdrDB)
Yang, Z., Ye, Z., Qiu, J., Feng, R., Li, D., Hsieh, C., Allcock, J., & Zhang, S. (2023) · Communications Chemistry · doi:10.1038/s42004-023-00920-7 · Cited by 24
Metadata
- Authors
- Hauser, K., Negron, C., Albanese, S. K., Ray, S., Steinbrecher, T., Abel, R., Chodera, J. D., & Wang, L.
- Venue
- Communications Biology
- Published
- 2018-06-13
- Volume
- 1
- Issue
- 1
- Pages
- 70-70
- ISSN
- 2399-3642 (ISSN-L)
- OpenAlex
- W2951718918
- Cited by
- 94
- References
- 15
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. https://app.cochat.ai/papers/10.1038/s42003-018-0075-x
- The paper
- Hauser, K., Negron, C., Albanese, S. K., Ray, S., Steinbrecher, T., Abel, R., Chodera, J. D., & Wang, L. (2018). Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Communications Biology. https://doi.org/10.1038/s42003-018-0075-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.